BioCentury | May 30, 2020
Finance

Daily Chart: May follow-on frenzy

May ended with a whopping $9 billion in follow-on capital raised for life sciences companies, more than the four previous months combined. The follow-on market had gone largely quiet in March and April as the...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

With enrollment complete in the Phase I trial of Moderna’s COVID-19 vaccine, BARDA could spend as much as a half-billion dollars to bring mRNA-1273 across the finish line. The news came amid multiple updates for...
BC Extra | Dec 16, 2019
Company News

Architects behind Celgene takeout step down as Flagship adds another industry vet in Biondi

With the departure of BMS's Head of Strategy and BD Paul Biondi to Flagship Pioneering, two of the main executives behind the pharma's acquisition of Celgene have now stepped down. Robert Hershberg departed as EVP,...
BC Extra | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

Former FDA Commissioner Scott Gottlieb has been appointed to the advisory board of FasterCures , a center of the Milken Institute dedicated to speeding up and improving medical research. Gottlieb stepped down from FDA's top post...
BC Week In Review | Nov 30, 2018
Company News

Boston Scientific to acquire London-based BTG

Boston Scientific Corp. (NYSE:BSX) will acquire BTG plc (LSE:BTG) for about £3.3 billion ($4.2 million) in cash. BTG shareholders will receive 840p per share. The acquisition is expected to close 1H19. BTG develops products used...
BC Week In Review | Sep 14, 2018
Company News

Boston Scientific to acquire Augmenix for $500M

Boston Scientific Corp. (NYSE:BSX) will acquire Augmenix Inc. (Waltham, Mass.) for $500 million in cash up front and up to $100 million in sales milestones. Boston Scientific will gain Augmenix's SpaceOAR hydrogel, which is used...
BC Extra | Oct 9, 2017
Politics & Policy

Patient engagement panel to focus on trial participation

Improving clinical trial recruitment, retention and results communication will be the focus of the inaugural meeting of FDA's Patient Engagement Advisory Committee (PEAC) on Oct. 11-12. In background materials posted by FDA's Center for Devices...
BioCentury | Sep 8, 2017
Finance

Rig-ging an exit

Wellington Partners’ quick exit from Rigontec GmbH will not only be one of the firm’s best returns from its current fund, but could bolster its fund-raising efforts for a third life sciences fund. On Sept....
BC Extra | May 15, 2017
Company News

Duke-Margolis forms value-based payment consortium

The Duke-Margolis Center for Health Policy said a newly formed consortium intends to explore issues tied to value-based payments for drugs, devices and gene technologies. The center said the consortium aims to overcome legal and...
BC Week In Review | May 11, 2015
Financial News

Boston Scientific completes private placement of senior notes

Boston Scientific Corp. (NYSE:BSX), Natick, Mass.   Business: Cardiovascular   Date completed: 2015-05-07   Type: Private placement of senior notes   Raised: $1.9 billion   Investor: Existing investors   Underwriters: Barclays Capital; Citigroup; Deutsche Bank;...
Items per page:
1 - 10 of 421
BioCentury | May 30, 2020
Finance

Daily Chart: May follow-on frenzy

May ended with a whopping $9 billion in follow-on capital raised for life sciences companies, more than the four previous months combined. The follow-on market had gone largely quiet in March and April as the...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

With enrollment complete in the Phase I trial of Moderna’s COVID-19 vaccine, BARDA could spend as much as a half-billion dollars to bring mRNA-1273 across the finish line. The news came amid multiple updates for...
BC Extra | Dec 16, 2019
Company News

Architects behind Celgene takeout step down as Flagship adds another industry vet in Biondi

With the departure of BMS's Head of Strategy and BD Paul Biondi to Flagship Pioneering, two of the main executives behind the pharma's acquisition of Celgene have now stepped down. Robert Hershberg departed as EVP,...
BC Extra | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

Former FDA Commissioner Scott Gottlieb has been appointed to the advisory board of FasterCures , a center of the Milken Institute dedicated to speeding up and improving medical research. Gottlieb stepped down from FDA's top post...
BC Week In Review | Nov 30, 2018
Company News

Boston Scientific to acquire London-based BTG

Boston Scientific Corp. (NYSE:BSX) will acquire BTG plc (LSE:BTG) for about £3.3 billion ($4.2 million) in cash. BTG shareholders will receive 840p per share. The acquisition is expected to close 1H19. BTG develops products used...
BC Week In Review | Sep 14, 2018
Company News

Boston Scientific to acquire Augmenix for $500M

Boston Scientific Corp. (NYSE:BSX) will acquire Augmenix Inc. (Waltham, Mass.) for $500 million in cash up front and up to $100 million in sales milestones. Boston Scientific will gain Augmenix's SpaceOAR hydrogel, which is used...
BC Extra | Oct 9, 2017
Politics & Policy

Patient engagement panel to focus on trial participation

Improving clinical trial recruitment, retention and results communication will be the focus of the inaugural meeting of FDA's Patient Engagement Advisory Committee (PEAC) on Oct. 11-12. In background materials posted by FDA's Center for Devices...
BioCentury | Sep 8, 2017
Finance

Rig-ging an exit

Wellington Partners’ quick exit from Rigontec GmbH will not only be one of the firm’s best returns from its current fund, but could bolster its fund-raising efforts for a third life sciences fund. On Sept....
BC Extra | May 15, 2017
Company News

Duke-Margolis forms value-based payment consortium

The Duke-Margolis Center for Health Policy said a newly formed consortium intends to explore issues tied to value-based payments for drugs, devices and gene technologies. The center said the consortium aims to overcome legal and...
BC Week In Review | May 11, 2015
Financial News

Boston Scientific completes private placement of senior notes

Boston Scientific Corp. (NYSE:BSX), Natick, Mass.   Business: Cardiovascular   Date completed: 2015-05-07   Type: Private placement of senior notes   Raised: $1.9 billion   Investor: Existing investors   Underwriters: Barclays Capital; Citigroup; Deutsche Bank;...
Items per page:
1 - 10 of 421